You are here
OvaScience Adds $37M for Fertility Treatments
Boston-based OvaScience announced today that it has raised $37 million in a Series B financing, the proceeds of which it will pour into the development of infertility treatments based on stem cell science. The funding round was led by General Catalyst, with participation from BBT Capital Management Advisors, Cycad Group, Hunt BioVentures, RA Capital and existing investors Longwood Fund and Bessemer Venture Partners. OvaScience previously raised $6 million last July.